Score Overview
Tekla Life Sciences Investors fundamental performance
Between 2005 and 2025, revenue grew from $ 890K to $ 86M and net income grew from $ 44M to $ 85M. Revenue increased in 11 of those 20 years; net income in 12.
Across Tekla Life Sciences Investors's full reported history, from 1996 to 2025, revenue grew from $ 420K to $ 86M and net income grew from $ 21M to $ 85M. Revenue increased in 48% of the years measured; net income in 56%.
Tekla Life Sciences Investors currently holds a 20-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 21.24 | — |
1 Year2025-08-12 | $ 11.79 | 80.22% |
5 Years2021-08-12 | $ 12.55 | 69.27% |
10 Years2016-08-12 | $ 7.39 | 187.43% |
20 Years2006-08-11 | $ 2.40 | 8x |
30 Years1996-08-12 | $ 0.80 | 26x |
All Time1992-05-04 | $ 0.85 | 25x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | 30 Years1996-08-12 | All Time1992-05-04 |
|---|---|---|---|---|---|---|---|
| Price | $ 21.24 | $ 11.79 | $ 12.55 | $ 7.39 | $ 2.40 | $ 0.80 | $ 0.85 |
| Return | — | 80.22% | 69.27% | 187.43% | 8x | 26x | 25x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2025 | $ 86M | $ 85M | $ 75.54K |
| 2024 | $ 86M | $ 85M | $ 1.00 |
| 2023 | $ 23M | $ 22M | $ 15M |
| 2022 | -$ 103M | -$ 104M | $ 445.00 |
| 2021 | $ 65M | $ 64M | $ 990.00 |
| 2020 | $ 124M | $ 123M | $ 4M |
| 2019 | -$ 69M | -$ 70M | $ 1M |
| 2018 | $ 1M | $ 28M | $ 40.00 |
| 2017 | $ 69M | $ 68M | $ 615.31K |
| 2016 | $ 6M | -$ 11M | $ 9M |
| 2015 | $ 1M | $ 40M | $ 403.00 |
| 2014 | $ 876.79K | $ 89M | $ 2.34K |
| 2013 | $ 516.76K | $ 84M | $ 36.58K |
| 2012 | $ 2M | $ 77M | $ 689.00 |
| 2011 | $ 570K | $ 37M | |
| 2010 | $ 1M | $ 10M | |
| 2009 | $ 460K | -$ 21M | $ 5M |
| 2008 | $ 1M | $ 60M | |
| 2007 | $ 2M | $ 50M | |
| 2006 | $ 2M | -$ 21M | |
| 2005 | $ 890K | $ 44M | |
| 2004 | $ 320K | $ 7M | $ 700K |
| 2003 | $ 610K | $ 38M | $ 1M |
| 2002 | $ 940K | -$ 50M | $ 100K |
| 2001 | $ 1M | -$ 95M | $ 400K |
| 1998 | $ 140K | -$ 30M | |
| 1997 | $ 320K | $ 15M | $ 100K |
| 1996 | $ 420K | $ 21M | $ 200K |
Explore beyond HQL
You're looking at Tekla Life Sciences Investors. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
